Melanotan: A Literature Course on What the Published Studies Describe

This page is for educational purposes only and is not medical advice; consult a licensed physician before making any health decision. This course summarises what the published literature reports about melanotan peptides. It does not describe a protocol, and it does not tell anyone what to do.

Module 1: What Melanotan Is and How It Has Been Studied

"Melanotan" is a colloquial umbrella term for synthetic analogues of alpha-melanocyte-stimulating hormone (α-MSH), a peptide hormone derived from the proopiomelanocortin (POMC) precursor. The scientific literature rarely uses the popular name. Instead, papers refer to specific compounds by their laboratory designations: NDP-α-MSH (also written afamelanotide or melanotan-I) and MTII (melanotan-II), a cyclic, shortened analogue.

Class and origin

These molecules belong to the melanocortin agonist class. Their parent hormone is produced from POMC, and rodent work has examined how POMC processing itself is regulated — for example, a mouse study reported that CAPS2 deficiency induced proopiomelanocortin accumulation in the pituitary and affected food intake behaviour (PMID 32891671). That background matters because melanotan analogues were designed to be more stable and more potent at melanocortin receptors than the natural peptide.

How the literature positions these peptides

A 2024 review of recommended tool compounds for the melanocortin receptor family catalogued which agonists and antagonists researchers should use when interrogating each receptor subtype, framing these peptides principally as pharmacological probes rather than consumer products (PMID 39296259). Elsewhere, MTII appears as a reference agonist in assay development — a 2021 paper described a zebrafish bioassay for screening therapeutic candidates based on melanotrophic activity, using pigment responses as a readable endpoint (PMID 34502223).

Forms described

• Linear α-MSH analogues such as NDP-α-MSH, studied for pigmentation and receptor targeting.
• Cyclic analogues such as MTII, used in central nervous system and topical experiments.
• Conjugates, in which a melanocortin ligand is chemically attached to a payload — a 2020 paper developed ligand-drug conjugates targeting melanoma through the overexpressed melanocortin 1 receptor (PMID 33073191).

Limits of the evidence in Module 1. The verified literature here is descriptive and preclinical. None of these papers established that the popularly traded material sold under the name "melanotan" is identical in purity, sequence or content to the characterised compounds used in laboratories. Terminology in consumer settings is inconsistent, and the studies cited did not test unregulated product.

Module 2: Mechanism as Described in the Literature

Melanocortin signalling runs through a family of G protein-coupled receptors. The 2024 tool-compound review organised the pharmacology of these GPCRs and the ligands used to study each one, underlining that selectivity between subtypes is a central experimental problem (PMID 39296259).

MC1R and pigmentation

The melanocortin 1 receptor sits on melanocytes. Because it is overexpressed on melanoma cells, a 2020 study exploited MC1R as a delivery address for ligand-drug conjugates directed at melanoma (PMID 33073191). Pigment change is also the endpoint that made the 2021 zebrafish system workable as a melanotrophic activity screen (PMID 34502223).

MC4R, appetite and downstream circuits

The melanocortin 4 receptor is the principal central node. A 2020 study reported that melanocortin regulation of feeding involved histaminergic neurons via perifornical lateral hypothalamic MC4 receptors (PMID 32244183). An earlier rodent study reported that amygdalar opioids modulated hypothalamic melanocortin-induced anorexia, describing a cross-talk between opioid and melanocortin systems in the control of food intake (PMID 19136019). At the molecular level, researchers reported that glucose-regulated protein 78 bound to and regulated the melanocortin-4 receptor, a chaperone interaction affecting receptor handling (PMID 30209265).

Limits of the evidence in Module 2. Mechanistic mapping was done in cells, fish and rodents. Receptor pharmacology in a dish does not predict what happens in an intact human, and the cited papers did not claim it would. Subtype selectivity of any given analogue is a known limitation the tool-compound review explicitly addressed (PMID 39296259).

Module 3: Reported Outcomes by Study

The table below organises what each verified study used as a model and what researchers reported. No benefit is implied; these are descriptions of experimental findings.

Reading the outcome literature carefully

Two patterns stand out. First, most melanocortin outcome work is about the system, not about a consumer peptide: the cardiac study activated the CNS leptin-melanocortin system and reported restored cardiac function in an infarction model (PMID 33532666), which is a statement about a signalling pathway in animals. Second, where a named melanotan analogue was used, it was often applied in an unusual route or setting — for example topical MTII in the melanoma suppression study (PMID 31968661).

Limits of the evidence in Module 3. These are animal, fish and cell experiments with mechanistic endpoints. None of the verified studies were human efficacy trials of melanotan for tanning, appetite or libido, and none of them reported an outcome that can be generalised to a person. Results in lean rats, for instance, were explicitly framed as phenotype-dependent (PMID 29566460).

Module 4: Melanotan Side Effects: What Studies Report

Adverse events associated with melanotan appear in the literature mainly as case reports and dermatology reviews describing people who acquired the peptide outside medical care.

Priapism

A 2019 BMJ Case Reports paper documented melanotan-induced priapism, a prolonged and painful erection that constitutes a urological emergency, in a case the authors titled "a hard-earned tan" (PMID 30796078). The report attributed the event to melanotan use and described it as a recognised hazard of these melanocortin agonists.

Pigmented lesions and eruptive nevi

A 2019 review in the American Journal of Clinical Dermatology examined eruptive melanocytic nevi — the sudden appearance of multiple new moles — and catalogued reported triggers and associations for that phenomenon (PMID 31119650). Because melanocortin agonism acts directly on melanocytes, changes in existing or new pigmented lesions are a dermatological concern discussed in this context.

Why the melanoma literature cuts both ways

Researchers have used MC1R overexpression on melanoma cells as a targeting strategy (PMID 33073191), and a separate study reported that topical MTII suppressed melanoma via PTEN upregulation and COX-2 inhibition (PMID 31968661). Those are laboratory observations about tumour biology, not evidence that systemic melanotan use is safe for skin, and the eruptive nevi review makes clear that new pigmented lesions warrant clinical assessment rather than reassurance (PMID 31119650).

Limits of the evidence in Module 4. Case reports establish that an event occurred in one person; they cannot establish frequency, dose-response or causation across a population. The priapism report was a single case (PMID 30796078), and the nevi paper was a narrative review rather than a controlled study (PMID 31119650). There is no systematic adverse-event surveillance for unregulated melanotan products, so the published harms are best read as a floor, not a complete list.

Module 5: Pharmacokinetics Where Data Exist

Honest reporting here means acknowledging a gap. The verified literature reviewed for this course contains no human pharmacokinetic dataset for melanotan peptides — no absorption, distribution, half-life or clearance values that can be quoted with a citation. What the literature does address is the experimental handling of these molecules.

• Receptor-level disposition. Researchers reported that glucose-regulated protein 78 bound to and regulated the melanocortin-4 receptor, describing chaperone-dependent receptor regulation rather than plasma kinetics (PMID 30209265).
• Route matters. The melanoma suppression study applied MTII topically rather than systemically (PMID 31968661), and the cardiac study used long-term central nervous system activation of the leptin-melanocortin system (PMID 33532666). Exposure profiles from such routes are not interchangeable.
• Assay context. The zebrafish melanotrophic screen measured a biological response over a short observation window rather than compound concentrations (PMID 34502223).
• Tool-compound guidance. The 2024 review emphasised selecting appropriate ligands for each receptor subtype, an issue tied to potency and stability in experimental systems (PMID 39296259).

Limits of the evidence in Module 5. Because no verified human PK study is available here, this course states no half-life, no bioavailability figure and no dosing interval. Any number circulating without a peer-reviewed source behind it should be treated as unverified.

Module 6: Regulatory Status, Stated Factually

Melanotan-II has never been approved as a medicine in the United States or the European Union. Material offered under the melanotan name is commonly labelled research use only (RUO), a designation meaning it is intended for laboratory investigation and is not manufactured, tested or released to pharmaceutical standards for human administration. RUO labelling does not constitute regulatory clearance for human use.

A related but distinct compound, afamelanotide (an NDP-α-MSH analogue), has been authorised in some jurisdictions as a prescription implant for a specific rare condition. That approval applies to a defined product, manufacturer and indication, and does not extend to material sold generically as "melanotan".

In the compounding context, United States pharmacy compounding is governed by sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act, which restrict the bulk substances a compounder may use. Substances lacking an applicable monograph or approved-drug status face significant restrictions. Health agencies in several countries have issued public warnings about unlicensed tanning peptides, and the published case literature — including the melanotan-associated priapism report (PMID 30796078) and dermatological concern about new pigmented lesions (PMID 31119650) — is frequently cited in those communications.

This section is general regulatory information and is not legal advice. Rules differ by country and change over time.

Limits of the evidence in Module 6. Regulatory status is jurisdictional and time-sensitive. None of the verified scientific papers addressed legal status directly; they addressed pharmacology and clinical case observation.

What the Studies Did Not Test

Closing a literature course means naming the unanswered questions. Across the verified papers:

1. No human efficacy trial of melanotan for cosmetic tanning appears in this evidence set. Pigment endpoints were measured in zebrafish (PMID 34502223), not in people seeking tanning.
2. No long-term human safety follow-up. The adverse-event literature here is a single case report (PMID 30796078) and a review of a lesion phenomenon (PMID 31119650).
3. No human dosing or pharmacokinetic characterisation is present, so no dose is stated anywhere on this page.
4. No testing of unregulated product. Studies used characterised laboratory compounds; the identity and purity of material circulating under the melanotan name was not assessed.
5. Translation gaps. Findings such as restored cardiac function after myocardial infarction via CNS leptin-melanocortin activation (PMID 33532666) and enhanced muscle responses in inherently lean rats (PMID 29566460) were animal observations about a pathway, not about a marketed peptide.
6. Interaction effects are only sketched. Opioid modulation of melanocortin-induced anorexia was shown in rodents (PMID 19136019), with no human counterpart in this set.

Readers comparing sources should note that popular claims about melanotan typically travel far ahead of the published record. Where the literature is silent, this course stays silent. Anyone with questions about pigmented skin lesions, sexual-function symptoms or any peptide should raise them with a licensed physician.

References

• Melanotan-induced priapism: a hard-earned tan (BMJ Case Reports, 2019)
• Restoration of Cardiac Function After Myocardial Infarction by Long-Term Activation of the CNS Leptin-Melanocortin System (JACC: Basic to Translational Science, 2021)
• Eruptive Melanocytic Nevi: A Review (American Journal of Clinical Dermatology, 2019)
• Zebrafish Bioassay for Screening Therapeutic Candidates Based on Melanotrophic Activity (International Journal of Molecular Sciences, 2021)
• Glucose-regulated protein 78 binds to and regulates the melanocortin-4 receptor (Experimental & Molecular Medicine, 2018)
• Development of Ligand-Drug Conjugates Targeting Melanoma through the Overexpressed Melanocortin 1 Receptor (ACS Pharmacology & Translational Science, 2020)
• Melanocortin regulation of histaminergic neurons via perifornical lateral hypothalamic melanocortin 4 receptors (Molecular Metabolism, 2020)
• Recommended Tool Compounds for the Melanocortin Receptor (MCR) G Protein-Coupled Receptors (GPCRs) (ACS Pharmacology & Translational Science, 2024)
• Topical MTII Therapy Suppresses Melanoma Through PTEN Upregulation and Cyclooxygenase II Inhibition (International Journal of Molecular Sciences, 2020)
• Inherently Lean Rats Have Enhanced Activity and Skeletal Muscle Response to Central Melanocortin Receptors (Obesity, 2018)
• Amygdalar opioids modulate hypothalamic melanocortin-induced anorexia (Physiology & Behavior, 2009)
• CAPS2 deficiency induces proopiomelanocortin accumulation in pituitary and affects food intake behavior in mice (Neuroscience Letters, 2020)